Randall Smith, MD
Orthopaedic Surgery · Philadelphia, PANPI 1427056555
Payments from drug & device makers
Across 237 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$803
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$758
- Scilex Pharmaceuticals Inc.$432
- Biodelivery Sciences International, Inc.$311
- Zyla Life Sciences, Inc.$246
- Sentynl Therapeutics, Inc.$172
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,769100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 47 | $803 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 51 | $758 |
| Scilex Pharmaceuticals Inc. | 22 | $432 |
| Biodelivery Sciences International, Inc. | 13 | $311 |
| Zyla Life Sciences, Inc. | 21 | $246 |
| Sentynl Therapeutics, Inc. | 17 | $172 |
| Amgen | 11 | $134 |
| Merck | 6 | $91 |
| Arbor Pharmaceuticals, Inc. | 6 | $81 |
| Hikma Pharmaceuticals USA | 5 | $80 |
| Daiichi Sankyo Inc. | 5 | $74 |
| Averitas Pharma Inc. | 3 | $71 |
| Electronic Waveform Lab, Inc. | 2 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $53 |
| Assertio Therapeutics, Inc. | 3 | $42 |
| AstraZeneca | 3 | $36 |
| Vertex | 2 | $35 |
| Redhill Biopharma Inc. | 2 | $34 |
| Valinor Pharma, LLC | 2 | $33 |
| MDD US Operations, LLC | 1 | $27 |
| Virtus Pharmaceuticals LLC | 2 | $27 |
| ERMI LLC | 1 | $27 |
| Almatica Pharma LLC | 1 | $23 |
| GRT US Holding, Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $20 |
| Kaleo, Inc. | 1 | $16 |
| Shionogi Inc | 1 | $14 |
| Pernix Therapeutics Holdings, Inc. | 1 | $14 |
| Forte Bio-pharma LLC | 1 | $13 |
| West Therapeutics Development, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BELBUCA$114
How this compares
$3,769 in reported general payments places this provider in the 50th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 66 | $66,770 |
| RelistorMethylnaltrexone Bromide | 14 | $32,393 |
| BelbucaBuprenorphine Hcl | 22 | $16,746 |
| Xtampza ErOxycodone Myristate | 36 | $16,653 |
| Oxycodone Hcl | 491 | $12,696 |
| MovantikNaloxegol Oxalate | 27 | $10,815 |
| Lidocaine | 83 | $9,295 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 103 | $3,482 |
| Buprenorphine | 20 | $2,698 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 73 | $2,103 |
| Naloxone Hcl | 23 | $1,646 |
| Morphine Sulfate ErMorphine Sulfate | 83 | $1,407 |
| Celecoxib | 30 | $1,349 |
| Gabapentin | 82 | $1,300 |
| Doxepin Hcl | 31 | $1,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $803 | $33,39958 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $758 | $32,39314 claims |
| Redhill Biopharma Inc.Movantik | $34 | $10,81527 claims |
| Hikma Pharmaceuticals USABuprenorphine | $80 | $2,69820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,048 orthopaedic surgery providers in Pennsylvania.
Other orthopaedic surgery in Philadelphia
- John FenlinPhiladelphia$5.9M
- Alexander VaccaroPhiladelphia$4.5M
- Joseph AbboudPhiladelphia$4.1M
- Samir MehtaPhiladelphia$3.7M
- Surena NamdariPhiladelphia$1.8M
- Craig IsraelitePhiladelphia$938K
- Andrew KuntzPhiladelphia$732K
- Neil ShethPhiladelphia$633K
- Vahid EntezariPhiladelphia$487K
- Amrit KhalsaPhiladelphia$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.